Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (121-130 of 197) with videos related to

Pageof 20
Sort By:
Journal for Immunotherapy of Cancer|May 20, 2021
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitorsTomoko Kobayashi, Shintaro Iwama, Daisuke Sugiyama, et al.
Japanese Journal of Clinical Oncology|January 9, 2022
Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancerKeiju Aokage, Masahiro Tsuboi, Yoshitaka Zenke, et al.
Cancer Immunology Research|November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor MicroenvironmentAyaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Inflammatory Bowel Diseases|May 15, 2020
Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease PatientsKentaro Murate, Keiko Maeda, Masanao Nakamura, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2015
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humansMakoto Miyara, Driss Chader, Edouard Sage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Life Science Alliance|March 3, 2022
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockadeYuki Miyai, Daisuke Sugiyama, Tetsunari Hase, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumoniaTakuya Ueda, Keiju Aokage, Sachiyo Mimaki, et al.
Cell Reports|August 31, 2022
A bifurcation concept for B-lymphoid/plasmacytoid dendritic cells with largely fluctuating transcriptome dynamicsKeiki Nagaharu, Yasuhiro Kojima, Haruka Hirose, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
Pageof 20

Showing results (121-130 of 197) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|May 20, 2021
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitorsTomoko Kobayashi, Shintaro Iwama, Daisuke Sugiyama, et al.
Japanese Journal of Clinical Oncology|January 9, 2022
Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancerKeiju Aokage, Masahiro Tsuboi, Yoshitaka Zenke, et al.
Cancer Immunology Research|November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor MicroenvironmentAyaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Inflammatory Bowel Diseases|May 15, 2020
Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease PatientsKentaro Murate, Keiko Maeda, Masanao Nakamura, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2015
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humansMakoto Miyara, Driss Chader, Edouard Sage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Life Science Alliance|March 3, 2022
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockadeYuki Miyai, Daisuke Sugiyama, Tetsunari Hase, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumoniaTakuya Ueda, Keiju Aokage, Sachiyo Mimaki, et al.
Cell Reports|August 31, 2022
A bifurcation concept for B-lymphoid/plasmacytoid dendritic cells with largely fluctuating transcriptome dynamicsKeiki Nagaharu, Yasuhiro Kojima, Haruka Hirose, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
Pageof 20